Globus Medical Inc. Class A Common Stock vs Honda Motor Company Ltd. Common Stock — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Honda Motor Company Ltd. Common Stock trades at $33.7 (market cap $43.65B). The key difference: Honda Motor Company Ltd. Common Stock is far larger — about 4.3× Globus Medical Inc. Class A Common Stock's market cap, and Honda Motor Company Ltd. Common Stock pays a 3.98% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Honda Motor Company Ltd. Common Stock for 6 Days on average.
| GMED | HMC | |
|---|---|---|
Market Cap | $10.25B | $43.65B |
Volume | 1,059,528 | 707,941 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $33.45 |
52-Week Low | $58.33 | $23.49 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $9.76B | $40.82B |
Dividend Yield | — | 3.98% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Honda Motor Co. (HMC) trades at $33.33, up 2.05% with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with revenue growth to $22.5T in 2026 but negative net income margins, while valuation metrics appear attractive with P/S of 0.32 and EV/EBITDA of 4.92. Recent news highlights strategic investments in hybrid technology and cost-cutting initiatives.
HMC presents a value opportunity with reasonable valuations and positive earnings surprises, though profitability challenges and competitive pressures create headwinds. Analyst consensus leans moderate buy with institutional interest, but investors should weigh cost reduction progress against margin pressures in the evolving auto industry.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Honda Motor manufactures automobiles, motorcycles, power products, and related financial services. Its brands serve consumer and commercial transportation markets globally.
Read more on HMC →